Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
HTG Molecular Diagnostics Announces Pricing of $20.0 Million Aggregate Financing, Consisting of $16.6 Million Public Offering of Common Stock and $3.5 Million Concurrent Private Placement
-
Amarin Corporation (AMRN) Symphony Data On An Uptrend - Cantor Fitzgerald
-
Freddie Mac Prices $1.17 Billion Seniors Housing Multifamily K Certificates
-
Apex Technology Acquisition Corporation Announces Closing of $350,000,000 Initial Public Offering
-
Apex Technology Acquisition Corporation Announces Closing of $350,000,000 Initial Public Offering
-
HTG Molecular Diagnostics (HTGM) Announces Proposed Common Share Offering
-
HTG Molecular Diagnostics Announces Proposed Public Offering of Common Stock
-
Freddie Mac Announces Pricing of $516 Million Multifamily Small Balance Loan Securitization
-
Exagen (XGN) IPO Opens 20% Higher
-
Evolent Health to Participate in Upcoming Investor Conference
-
Axogen, Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference
-
Axogen, Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference
-
Exagen Inc (XGN) Prices 3.6M Share IPO at $14/Sh
-
Provention Bio Inc. (PRVB) Prices 5M Share Common Offering at $8/Sh
-
Provention Bio Announces Pricing of $40 Million Public Offering of Common Stock
-
Exagen Inc. Announces Pricing of Initial Public Offering
-
Exagen Inc. Announces Pricing of Initial Public Offering
-
Provention Bio Inc. (PRVB) Plans Public Offering of Common Stock
-
Provention Bio Announces Proposed Public Offering of Common Stock
-
Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Acadia Pharma (ACAD) Prices 6.25M Share Offering at $40/Sh
-
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
-
BioDelivery Sciences Announces Participation in Upcoming Investor Conferences
-
BioDelivery Sciences Announces Participation in Upcoming Investor Conferences
-
CareDx to Participate in the Cantor Fitzgerald Global Healthcare Conference
-
Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2019 and Provides Corporate Update
-
Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2019 and Provides Corporate Update
-
Apex Technology Acquisition Corp. (APXT) Prices 30.5M Unit IPO at $10/Unit
-
Oil falls as supply worries fade; stocks edge higher
-
Apex Technology Acquisition Corporation Announces Pricing of $305,000,000 Initial Public Offering
-
Apex Technology Acquisition Corporation Announces Pricing of $305,000,000 Initial Public Offering
-
NLA Provides Amarin's (AMRN) Vascepa With Yet Another Positive Recommendation - Cantor Fitzgerald
-
Orchid Island Capital Announces September 2019 Monthly Dividend and August 31, 2019 RMBS Portfolio Characteristics
-
BGC Partners' & Cantor Fitzgerald's Charity Day Drives Impact & Inspires Unity
-
Making A Difference & Rewriting A Narrative, Cantor Fitzgerald's And BGC Partners' Charity Day Raises Funds & Spirits
-
ViewRay's (VRAY) ASTRO Attendance Could Be A Positive Catalyst - Cantor
-
Chiasma (CHMA) KOL Breakfast Offers New Positive Mycapssa Data - Cantor
-
Cantor Fitzgerald Downgrades Tocagen Inc. (TOCA) to Neutral
-
International Money Express Inc. (IMXI) Prices 5.217M Share Secondary Offering at $12.75/Sh
-
Fate Therapeutics (FATE) Prices 8.6M Share Offering at $17.50/Sh
-
Fate Therapeutics Announces Pricing of Public Offering of Common Stock
-
Fate Therapeutics Announces Pricing of Public Offering of Common Stock
-
International Money Express, Inc. Announces Pricing of Secondary Public Offering
-
International Money Express, Inc. Announces Pricing of Secondary Public Offering
-
Visibility on Amarin (AMRN) sNDA Removes Overhang - Cantor Fitzgerald
-
Cantor Fitzgerald Starts Ceridian HCM Holding Inc. (CDAY) at Overweight
-
Mereo BioPharma to Announce Interim Financial Results for the Six Months Ended June 30, 2019 and Provide Corporate Update on September 17, 2019
-
Mereo BioPharma to Announce Interim Financial Results for the Six Months Ended June 30, 2019 and Provide Corporate Update on September 17, 2019
-
TD Ameritrade Institutional Expands Award-Winning Model Market Centerâ„¢ With More Investment Portfolios From More Model Providers

